Plerixafor
Back to searchMolecule Structure
Scientific Name
Plerixafor
Description of the Drug
Plerixafor is a selective chemokine receptor (CXCR4) antagonist used with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06809
http://www.drugbank.ca/drugs/DB06809
Brand Name(s)
Mozobil
Company Owner(s)
Genzyme Corp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| C-X-C chemokine receptor type 4 | SINGLE PROTEIN | PARTIAL AGONIST | CHEMBL2107 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL19038 | |
| PharmGKB | PA165958410 | |
| Human Metabolome Database | HMDB0015681 | |
| DrugBank | DB06809 | |
| PubChem: Thomson Pharma | 14933416 | |
| PubChem | 65015 | |
| LINCS | LSM-36826 | |
| Nikkaji | J579.015H | |
| BindingDB | 50035696 | |
| EPA CompTox Dashboard | DTXSID70869520 | |
| DrugCentral | 4410 | |
| ChemicalBook | CB11011749 | |
| Guide to Pharmacology | 844 | |
| rxnorm | MOZOBIL | PLERIXAFOR |
| ChEBI | 125354 | |
| ZINC | ZINC000022443609 |
